RxDoctor Payments Data

Alberto Grana Santini, MD

Endocrinology, Diabetes & Metabolism · Caguas, PRNPI 1366829731

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 317 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations.

$7,550in general payments, 2019–2025

Across 317 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Eli Lilly Export S.A. Puerto Rico Branch$945
  • Novo Nordisk$824
  • Sanofi-aventis U.S. LLC$760
  • AstraZeneca$652
  • Medtronic$641
  • plus $3K from 13 others

What the payments were for

  • Travel & lodging$4716%
  • Food & beverage$7,07494%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim39$1,081
Eli Lilly Export S.A. Puerto Rico Branch42$945
Novo Nordisk47$824
Sanofi-aventis U.S. LLC36$760
AstraZeneca29$652
Medtronic9$641
Johnson & Johnson24$559
Dexcom, Inc.18$404
Amgen10$280
Lilly USA, LLC9$267
Merck9$248
PBG Puerto Rico LLC10$187
Abbott9$164
Bayer Puerto Rico Inc.6$140
AbbVie8$132
Radius Health, Inc.5$111
Bayer4$92
Pfizer Pharmaceuticals LLC2$47
Vifor Pharma, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,550 in reported general payments places this provider in the 65th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,446
Medicare patients
16
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide404$414,410
TrulicityDulaglutide218$226,917
MounjaroTirzepatide196$218,640
Trijardy XrEmpaglifloz/Linaglip/Metformin203$162,110
FarxigaDapagliflozin Propanediol144$125,526
Synjardy XrEmpagliflozin/Metformin Hcl167$118,769
JardianceEmpagliflozin130$106,933
TradjentaLinagliptin60$47,861
HumalogInsulin Lispro246$36,953
SynthroidLevothyroxine Sodium417$35,751
LantusInsulin Glargine,hum.Rec.Anlog314$31,272
Xigduo XrDapaglifloz Propaned/Metformin17$24,464
GlyxambiEmpagliflozin/Linagliptin30$19,789
Jentadueto XrLinagliptin/Metformin Hcl24$17,929
Janumet XrSitagliptin Phos/Metformin Hcl29$17,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Insulin Lispro$267$492,908794 claims
Boehringer IngelheimTrijardy Xr, Synjardy Xr, Jardiance, Tradjenta, Glyxambi$1,081$482,002631 claims
Novo NordiskOzempic, Novolog$824$419,456426 claims
AstraZenecaFarxiga$652$125,526144 claims
MerckJanumet Xr, Janumet, Januvia$248$48,10467 claims
Sanofi-aventis U.S. LLCLantus, Soliqua 100-33$760$42,021326 claims
AbbVieSynthroid$132$35,751417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →